RT Journal Article
SR Electronic
T1 Therapeutic Efficacy and Inhibitory Mechanism of Regorafenib Combined With Radiation in Colorectal Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 3217
OP 3224
DO 10.21873/invivo.12157
VO 34
IS 6
A1 YU-CHANG LIU
A1 I-TSANG CHIANG
A1 JING-GUNG CHUNG
A1 JUNG-HUNG HSIEH
A1 CHIH-HUNG CHIANG
A1 MAO-CHI WENG
A1 FEI-TING HSU
A1 YUAN-HAO LEE
A1 CHENG-SHYONG CHANG
A1 SONG-SHEI LIN
YR 2020
UL http://iv.iiarjournals.org/content/34/6/3217.abstract
AB Background: Although both chemotherapy and radiotherapy (RT) can sufficiently maintain tumor suppression of colorectal cancer (CRC), these treatments may trigger the expression of nuclear factor kappa B (NF-κB) and compromise patients' survival. Regorafenib suppresses NF-κB activity in various tumor types. However, whether regorafenib may act as a suitable radiosensitizer to enhance therapeutic efficacy of RT remains unknown. Materials and Methods: Here, we established a CRC-bearing animal model to investigate the therapeutic efficacy of regorafenib in combination with RT, through measurement of tumor growth, body weight, whole-body computed tomography (CT) scan and immunohisto-chemistry staining. Results: Smallest tumor size and weight were found in the combination treatment group. In addition, RT-induced up-regulation of NF-κB and downstream proteins were diminished by regorafenib. Moreover, the body weight and liver pathology in the treated group were similar to those of the non-treated control group. Conclusion: Regorafenib may enhance the anti-CRC efficacy of RT.